Skip to main content

Table 5 Characteristics of adjuvant therapy

From: Comparative study between colonic metallic stent and anal tube decompression for Japanese patients with left-sided malignant large bowel obstruction

  TDT group (n = 33) CMS group (n = 26)
Adjuvant therapy
 Stage II
  Negative 7 6
  Oral 5FU/leucovorin or oral 5FU 3 2
  Capecitabine + oxaliplatin 0 3
  mFOLFOX6 1 0
 Stage III
  Negative 2 2
  Oral 5FU/leucovorin or oral 5FU 7 1
  Capecitabine + oxaliplatin bevacizumab 1 2
  unknown 1 1
 Stage IV
  Best supportive care 3 2
  Oral 5FU/leucovorin or oral 5FU 1 2
  mFOLFOX6 bevacizumab 3 2
  mFOLFOX6 + panitumumab 0 1
  Capecitabine + oxaliplatin bevacizumab 1 2
  S1 + oxaliplatin + bevacizumab 1 0
  Others 2 0